A Benefit-Risk Assessment of Class III Antiarrhythmic Agents

With β-blockers as the exception, increasing doubt is emerging on the value of antiarrhythmic drug therapy following a series of trials that have either shown no mortality benefit or even an excess mortality. Vaughan Williams class I drugs are generally avoided in patients with structural heart disease, and class IV drugs are avoided in heart failure. Unfortunately, arrhythmias are a growing problem due to an increase in the incidence of atrial fibrillation and sudden death. The population is becoming older and more patients survive for a longer time period with congestive heart failure, which again increases the frequency of both supraventricular as well as ventricular arrhythmias.Class III antiarrhythmic drugs act by blocking repolarising currents and thereby prolong the effective refractory period of the myocardium. This is believed to facilitate termination of re-entry tachyarrhythmias. This class of drugs is developed for treatment of both supraventricular and ventricular arrhythmias. Amiodarone, sotalol, dofetilide, and ibutilide are examples of class III drugs that are currently available. Amiodarone and sotalol have other antiarrhythmic properties in addition to pure class III action, which differentiates them from the others. However, all have potential serious adverse events. Proarrhythmia, especially torsade de pointes, is a common problem making the benefit-risk ratio of these drugs a key question.Class III drugs have been evaluated in different settings: primary and secondary prevention of ventricular arrhythmias and in treatment of atrial fibrillation or flutter. Based on existing evidence there is no routine indication for antiarrhythmic drug therapy other than β-blockers in patients at high risk of sudden death. Subgroup analyses of trials with amiodarone and dofetilide suggest that patients with atrial fibrillation may have a mortality reduction with these drugs. However, this needs to be tested in a prospective trial. Similarly, subgroups that will benefit from prophylactic treatment with class III antiarrhythmic drugs may be found based on QT-intervals or — in the future — from genetic testing.Class III drugs are effective in converting atrial fibrillation to sinus rhythm and for the maintenance of sinus rhythm after conversion. This is currently by far the most important indication for this class of drugs. As defined by recent guidelines, amiodarone and dofetilide have their place as second-line therapy except for patients with heart failure where they are first line therapy being the only drugs where the safety has been documented for this group of high risk patients.

[1]  Michael R. Rosen,et al.  The 'Sicilian Gambit' - A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms , 1991 .

[2]  J. Tsikouris,et al.  A Review of Class III Antiarrhythmic Agents for Atrial Fibrillation: Maintenance of Normal Sinus Rhythm , 2001, Pharmacotherapy.

[3]  J. Arrowsmith,et al.  UK-68,798: a novel, potent and highly selective class III antiarrhythmic agent which blocks potassium channels in cardiac cells. , 1991, The Journal of pharmacology and experimental therapeutics.

[4]  C Antzelevitch,et al.  Cellular basis for the normal T wave and the electrocardiographic manifestations of the long-QT syndrome. , 1998, Circulation.

[5]  C Antzelevitch,et al.  The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. , 2000, European heart journal.

[6]  P. Sager New advances in class III antiarrhythmic drug therapy , 2000, Current opinion in cardiology.

[7]  F. Morady,et al.  Immediate reproducibility of clinical and nonclinical forms of induced ventricular tachycardia. , 1986, The American journal of cardiology.

[8]  M. Radford,et al.  Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure. CHF-STAT Investigators. , 1996, Circulation.

[9]  S. Yabek,et al.  Electrophysiologic effects of the levo- and dextrorotatory isomers of sotalol in isolated cardiac muscle and their in vivo pharmacokinetics. , 1986, Journal of the American College of Cardiology.

[10]  C Antzelevitch,et al.  Clinical relevance of cardiac arrhythmias generated by afterdepolarizations. Role of M cells in the generation of U waves, triggered activity and torsade de pointes. , 1994, Journal of the American College of Cardiology.

[11]  J F Leclercq,et al.  Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. , 1989, American heart journal.

[12]  Bertram Pitt,et al.  Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction , 1996, The Lancet.

[13]  Y Rudy,et al.  Pause induced early afterdepolarizations in the long QT syndrome: a simulation study. , 1999, Cardiovascular research.

[14]  M. Keller,et al.  A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. , 1997, The New England journal of medicine.

[15]  M. Brodsky,et al.  Efficacy and Safety of Oral Dofetilide in Converting to and Maintaining Sinus Rhythm in Patients With Chronic Atrial Fibrillation or Atrial Flutter: The Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) Study , 2000, Circulation.

[16]  J. Lynch,et al.  Comparative effects of increased extracellular potassium and pacing frequency on the class III activities of methanesulfonanilide IKr blockers dofetilide, D-sotalol, E-4031, and MK-499. , 1994, Journal of cardiovascular pharmacology.

[17]  H. Elming,et al.  Survival after withdrawal of dofetilide in patients with congestive heart failure and a short baseline QTc interval; a follow-up on the Diamond-CHF QT substudy. , 2003, European heart journal.

[18]  B. Lucchesi,et al.  Prevention of ventricular fibrillation by dextrorotatory sotalol in a conscious canine model of sudden coronary death. , 1985, American heart journal.

[19]  D. Roden,et al.  Pause-dependent polymorphic ventricular tachycardia during long-term treatment with dofetilide: a placebo-controlled, implantable cardioverter-defibrillator-based evaluation. , 2001, Journal of the American College of Cardiology.

[20]  K. Nademanee,et al.  Antiarrhythmic efficacy and electrophysiologic actions of amiodarone in patients with life-threatening ventricular arrhythmias: potent suppression of spontaneously occurring tachyarrhythmias versus inconsistent abolition of induced ventricular tachycardia. , 1982, American heart journal.

[21]  Thomas L. Lenz,et al.  Dofetilide, a New Class III Antiarrhythmic Agent , 2000, Pharmacotherapy.

[22]  R. Page,et al.  Azimilide dihydrochloride: a new class III anti-arrhythmic agent , 2000, Expert opinion on investigational drugs.

[23]  A. Camm,et al.  Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. , 1999, The New England journal of medicine.

[24]  H L Greene,et al.  Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. , 1991, The New England journal of medicine.

[25]  S. Doggrell,et al.  D-Sotalol: death by the SWORD or deserving of further consideration for clinical use? , 2000, Expert opinion on investigational drugs.

[26]  L. Horowitz,et al.  Proarrhythmic responses during electrophysiologic testing. , 1987, The American journal of cardiology.

[27]  R. Hauer,et al.  Genetic and molecular basis of cardiac arrhythmias : Impact on clinical management , 1999 .

[28]  J. Mason A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators. , 1993, The New England journal of medicine.

[29]  S. Hohnloser,et al.  Prevention of implantable-defibrillator shocks by treatment with sotalol. d,l-Sotalol Implantable Cardioverter-Defibrillator Study Group. , 1999, The New England journal of medicine.

[30]  S. S. Hull,et al.  K+ Channel Blockade in the Prevention of Ventricular Fibrillation in Dogs with Acute Ischemia and Enhanced Sympathetic Activity , 1995, Journal of cardiovascular pharmacology.

[31]  D. Roden Ibutilide and the treatment of atrial arrhythmias. A new drug--almost unheralded--is now available to US physicians. , 1996, Circulation.

[32]  A. Camm,et al.  The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. , 2000, Cardiovascular research.

[33]  E. Vitolo,et al.  Amiodarone versus quinidine in the prophylaxis of atrial fibrillation. , 1981, Acta cardiologica.

[34]  P. Sager,et al.  Frequency-dependent electrophysiologic effects of amiodarone in humans. , 1993, Circulation.

[35]  Dimarco Jp,et al.  Cardiovascular drugs. Dofetilide. , 2000 .

[36]  S. Lévy,et al.  Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists. , 1999, Circulation.

[37]  F. Charpentier,et al.  Electrophysiologic characteristics of cells spanning the left ventricular wall of human heart: evidence for presence of M cells. , 1995, Journal of the American College of Cardiology.

[38]  J Toyama,et al.  Amiodarone: ionic and cellular mechanisms of action of the most promising class III agent. , 1999, The American journal of cardiology.

[39]  QTc Interval as a Guide to Select Those Patients With Congestive Heart Failure and Reduced Left Ventricular Systolic Function Who Will Benefit From Antiarrhythmic Treatment With Dofetilide , 2001 .

[40]  S. Juul-Möller,et al.  Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. , 1990 .

[41]  L. Virág,et al.  Frequency-dependent Cardiac Electrophysiologic Effects of Tedisamil: Comparison With Quinidine and Sotalol , 1997, Journal of cardiovascular pharmacology and therapeutics.

[42]  P. Dorian,et al.  Electrophysiologic mechanisms of antiarrhythmic efficacy of a sotalol and class Ia drug combination: elimination of reverse use dependence. , 1997, Journal of the American College of Cardiology.

[43]  E. Carmeliet Electrophysiologic and voltage clamp analysis of the effects of sotalol on isolated cardiac muscle and Purkinje fibers. , 1985, The Journal of pharmacology and experimental therapeutics.

[44]  A. Camm,et al.  Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT , 1997, The Lancet.

[45]  B. Singh,et al.  Barium-induced nondriven action potentials as a model of triggered potentials from early afterdepolarizations: significance of slow channel activity and differing effects of quinidine and amiodarone. , 1990, Journal of the American College of Cardiology.

[46]  M. Pfisterer,et al.  Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS) , 1990, Journal of the American College of Cardiology.

[47]  C Antzelevitch,et al.  Acceleration‐Induced Action Potential Prolongation and Early Afterdepolarizations , 1998, Journal of cardiovascular electrophysiology.

[48]  J. Kalus,et al.  Dofetilide: A Class III-Specific Antiarrhythmic Agent , 2000, The Annals of pharmacotherapy.

[49]  E. Aliot,et al.  The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. , 1988, Progress in cardiovascular diseases.

[50]  L. Køber,et al.  Dofetilide: a class III anti-arrhythmic drug for the treatment of atrial fibrillation , 2000, Expert opinion on investigational drugs.

[51]  M. Malik,et al.  Measurement, interpretation and clinical potential of QT dispersion. , 2000, Journal of the American College of Cardiology.

[52]  Kenneth Egstrup,et al.  Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial , 2000, The Lancet.

[53]  R. Falk,et al.  Dofetilide: a new pure class III antiarrhythmic agent. , 2000, American heart journal.

[54]  M. Sanguinetti Modulation of potassium channels by antiarrhythmic and antihypertensive drugs. , 1992, Hypertension.

[55]  Bramahn . Singh,et al.  What niche will newer class III antiarrhythmic drugs occupy? , 2001, Current cardiology reports.

[56]  A. Camm,et al.  Amiodarone interaction with beta-blockers: analysis of the merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) databases. The EMIAT and CAMIAT Investigators. , 1999, Circulation.

[57]  R. Brooks,et al.  Pharmacology of Azimilide Dihydrochloride (NE-10064), A Class III Antiarrhythmic Agent , 1997 .

[58]  R. Hart,et al.  Atrial Fibrillation and Thromboembolism: A Decade of Progress in Stroke Prevention , 1999, Annals of Internal Medicine.

[59]  J. K. Gibson,et al.  Electrophysiology and pharmacology of ibutilide. , 1996, The American journal of cardiology.

[60]  B. Surawicz Electrophysiologic substrate of torsade de pointes: dispersion of repolarization or early afterdepolarizations? , 1989, Journal of the American College of Cardiology.

[61]  M. Janse,et al.  Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials , 1997, The Lancet.

[62]  M. Keating,et al.  MiRP1 Forms IKr Potassium Channels with HERG and Is Associated with Cardiac Arrhythmia , 1999, Cell.

[63]  L. Carlsson,et al.  Proarrhythmic effects of the class III agent almokalant: importance of infusion rate, QT dispersion, and early afterdepolarisations. , 1993, Cardiovascular research.

[64]  M Gent,et al.  Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone. , 2000, Circulation.

[65]  Robert Lemery,et al.  Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. , 1992, The New England journal of medicine.

[66]  H. Elming,et al.  The prognostic value of QTC interval and QT dispersion following myocardial infarction in patients treated with or without dofetilide , 2003, Clinical cardiology.

[67]  P. Dorian Mechanisms of action of class III agents and their clinical relevance. , 2000, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[68]  M Restivo,et al.  The electrophysiological mechanism of ventricular arrhythmias in the long QT syndrome. Tridimensional mapping of activation and recovery patterns. , 1996, Circulation research.

[69]  A. Capucci,et al.  Clinical Potential of Emerging Antiarrhythmic Agents , 1999, Drugs in R&D.

[70]  E. Antman,et al.  Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. , 1990, Circulation.

[71]  S. Hohnloser,et al.  Proarrhythmia with Class III Antiarrhythmic Drugs: Definition, Electrophysiologic Mechanisms, Incidence, Predisposing Factors, and Clinical Implications , 1995, Journal of cardiovascular electrophysiology.

[72]  E. Antman,et al.  Assessment of the efficacy and safety of antiarrhythmic therapy for chronic atrial fibrillation: observations on the role of trial design and implications of drug-related mortality. , 1992, American heart journal.

[73]  B. Fermini,et al.  Use‐Dependent Effects of the Class III Antiarrhythmic Agent NE‐10064 (Azimilide) on Cardiac Repolarization: Block of Delayed Rectifier Potassium and L‐Type Calcium Currents , 1995, Journal of cardiovascular pharmacology.

[74]  D. Roden,et al.  Extracellular potassium modulation of drug block of IKr. Implications for torsade de pointes and reverse use-dependence. , 1996, Circulation.

[75]  S. Hohnloser,et al.  Rhythm or rate control in atrial fibrillation—Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial , 2000, The Lancet.

[76]  V. Velebit,et al.  Aggravation and Provocation of Ventricular Arrhythmias by Antiarrhythmic Drugs , 1982, Circulation.

[77]  R. Prescott,et al.  CONTROLLED TRIAL OF SOTALOL FOR ONE YEAR AFTER MYOCARDIAL INFARCTION , 1982, The Lancet.

[78]  S. Hohnloser,et al.  Drug therapy : Sotalol , 1994 .

[79]  S Nattel,et al.  Effects of the chromanol 293B, a selective blocker of the slow, component of the delayed rectifier K+ current, on repolarization in human and guinea pig ventricular myocytes. , 1998, Cardiovascular research.

[80]  D. Wolfe,et al.  Ibutilide: a class III rapidly acting antidysrhythmic for atrial fibrillation or atrial flutter. , 2001, The Journal of emergency medicine.

[81]  M. Sanguinetti,et al.  Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents , 1990, The Journal of general physiology.

[82]  M. Morad,et al.  Tedisamil blocks the transient and delayed rectifier K+ currents in mammalian cardiac and glial cells. , 1990, The Journal of pharmacology and experimental therapeutics.

[83]  D. Roden Taking the “Idio” out of “Idiosyncratic”: Predicting Torsades de Pointes , 1998, Pacing and clinical electrophysiology : PACE.

[84]  F. Epstein,et al.  Electrocardiographic Findings Among the Adult Population of a Total Natural Community, Tecumseh, Michigan , 1965, Circulation.

[85]  B F Hoffman,et al.  Action Potential Prolongation and Induction of Abnormal Automaticity by Low Quinidine Concentrations in Canine Purkinje Fibers Relationship to Potassium and Cycle Length , 1985, Circulation research.

[86]  H. Doval,et al.  Randomised trial of low-dose amiodarone in severe congestive heart failure , 1994, The Lancet.

[87]  A. Schömig,et al.  Differential Effect of β‐Adrenergic Stimulation on the Frequency‐Dependent Electrophysiologic Actions of the New Class III Antiarrhythmics Dofetilide, Ambasilide, and Chromanol 293. , 1997 .

[88]  S. Nattel,et al.  Effects of the novel antiarrhythmic agent azimilide on experimental atrial fibrillation and atrial electrophysiologic properties. , 1998, Cardiovascular research.

[89]  Bramahn . Singh,et al.  Current Antiarrhythmic Drugs , 1999, Journal of cardiovascular electrophysiology.

[90]  S. Priori,et al.  Low penetrance in the long-QT syndrome: clinical impact. , 1999, Circulation.

[91]  Bramahn . Singh,et al.  Expanding Indications for the Use of Class III Agents in Patients at High Risk for Sudden Death , 1995, Journal of cardiovascular electrophysiology.

[92]  P. Polster,et al.  The adrenergic antagonism of amiodarone. , 1976, Biochemical pharmacology.

[93]  V. Fuster,et al.  ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation , 2001 .

[94]  Amiodarone to Prevent Recurrence of Atrial Fibrillation , 2000 .

[95]  C. Furberg,et al.  Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. , 1993, JAMA.

[96]  D. Snyders,et al.  Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence. , 1990, Circulation.

[97]  C Antzelevitch,et al.  Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes. , 1996, Journal of the American College of Cardiology.

[98]  A. Hall,et al.  QT dispersion as a predictor of long-term mortality in patients with acute myocardial infarction and clinical evidence of heart failure. , 1999, European heart journal.

[99]  S. Connolly,et al.  Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT , 1997, The Lancet.

[100]  C Antzelevitch,et al.  Chronic Amiodarone Reduces Transmural Dispersion of Repolarization in the Canine Heart , 1997, Journal of cardiovascular electrophysiology.

[101]  Bramahn . Singh,et al.  Antiarrhythmic actions of amiodarone: a profile of a paradoxical agent. , 1996, The American journal of cardiology.

[102]  M J Ackerman,et al.  The long QT syndrome: ion channel diseases of the heart. , 1998, Mayo Clinic proceedings.

[103]  Alfred P. Hallstrom,et al.  Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. , 1999 .

[104]  P. Dorian,et al.  Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. , 2002, The New England journal of medicine.

[105]  J. Williams,et al.  Maintenance of sinus rhythm with oral d,l-sotalol therapy in patients with symptomatic atrial fibrillation and/or atrial flutter. d,l-Sotalol Atrial Fibrillation/Flutter Study Group. , 1999, The American journal of cardiology.

[106]  T. Colatsky,et al.  Channel specificity in antiarrhythmic drug action. Mechanism of potassium channel block and its role in suppressing and aggravating cardiac arrhythmias. , 1990, Circulation.

[107]  E. Antman,et al.  Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. , 1993, The American journal of cardiology.

[108]  M. Sami,et al.  Dofetilide: a new class III antiarrhythmic agent. , 2001, The Canadian journal of cardiology.

[109]  M. Sanguinetti,et al.  Rate-dependent prolongation of cardiac action potentials by a methanesulfonanilide class III antiarrhythmic agent. Specific block of rapidly activating delayed rectifier K+ current by dofetilide. , 1993, Circulation research.

[110]  P C Deedwania,et al.  Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. , 1995, The New England journal of medicine.

[111]  P C Deedwania,et al.  Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators. , 1998, Circulation.

[112]  F. Lombardi,et al.  Daily reproducibility of electrophysiologic test results in malignant ventricular arrhythmia. , 1986, The American journal of cardiology.

[113]  J. Brachmann,et al.  Electrocardiographic and Clinical Predictors of Torsades de Pointes Induced by Almokalant Infusion in Patients with Chronic Atrial Fibrillation or Flutter: A Prospective Study , 1998, Pacing and clinical electrophysiology : PACE.

[114]  L. Horowitz,et al.  Proarrhythmic effects of antiarrhythmic drugs in patients with malignant ventricular arrhythmias evaluated by electrophysiologic testing. , 1988, Journal of the American College of Cardiology.

[115]  S. Yusuf,et al.  Effect of amiodarone on mortality after myocardial infarction: a double-blind, placebo-controlled, pilot study. , 1992, Journal of the American College of Cardiology.

[116]  Bramahn . Singh,et al.  Reviews: Pure Class III Antiarrhythmic Drugs: Focus on Dofetilide , 2000, Journal of cardiovascular pharmacology and therapeutics.

[117]  S. Priori,et al.  Sympathetic activation, ventricular repolarization and Ikr blockade: implications for the antifibrillatory efficacy of potassium channel blocking agents. , 1995, Journal of the American College of Cardiology.

[118]  M. Malik,et al.  QT Dispersion Has No Prognostic Information for Patients With Advanced Congestive Heart Failure and Reduced Left Ventricular Systolic Function , 2001, Circulation.

[119]  L. Køber,et al.  Efficacy of Dofetilide in the Treatment of Atrial Fibrillation-Flutter in Patients With Reduced Left Ventricular Function: A Danish Investigations of Arrhythmia and Mortality ON Dofetilide (DIAMOND) Substudy , 2001, Circulation.

[120]  K. Kuck,et al.  Implantable cardioverter defibrillator compared with antiarrhythmic drug treatment in cardiac arrest survivors (the Cardiac Arrest Study Hamburg). , 1994, American heart journal.

[121]  G. Butrous,et al.  Dofetilide, A Novel Class III Antiarrhythmic Agent , 1992, Journal of cardiovascular pharmacology.

[122]  A. Camm,et al.  What Should We Expect From the Next Generation of Antiarrhythmic Drugs? , 1999, Journal of cardiovascular electrophysiology.

[123]  U. Gerlach,et al.  Rate- and site-dependent effects of propafenone, dofetilide, and the new I(Ks)-blocking agent chromanol 293b on individual muscle layers of the intact canine heart. , 1999, Circulation.

[124]  D. Levy,et al.  Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. , 1998, Circulation.

[125]  Lippincott Williams Wilkins,et al.  The Sicilian gambit. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. , 1991, Circulation.

[126]  R. Fletcher,et al.  Class III drugs and congestive heart failure: focus on the congestive heart failure-survival trial of antiarrhythmic therapy. , 1999, The American journal of cardiology.